Anthrax - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Anthrax - Pipeline Review, H2 2016

Anthrax - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Anthrax - Pipeline Review, H2 2016
Published Jul 20, 2016
154 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Anthrax - Pipeline Review, H2 2016, provides an overview of the Anthrax pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anthrax, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anthrax
- The report reviews pipeline therapeutics for Anthrax by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anthrax therapeutics and enlists all their major and minor projects
- The report assesses Anthrax therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anthrax

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anthrax
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anthrax pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective

  
Source:
Document ID
GMDHC8284IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents29
  List of Tables91
  List of Figures101
Introduction111
  Global Markets Direct Report Coverage111
Anthrax Overview121
Therapeutics Development132
  Pipeline Products for Anthrax Overview131
  Pipeline Products for Anthrax Comparative Analysis141
Anthrax Therapeutics under Development by Companies152
Anthrax Therapeutics under Investigation by Universities/Institutes171
Anthrax Pipeline Products Glance183
  Late Stage Products181
  Clinical Stage Products191
  Early Stage Products201
Anthrax Products under Development by Companies213
Anthrax Products under Investigation by Universities/Institutes241
Anthrax Companies Involved in Therapeutics Development2528
  Aduro BioTech, Inc.251
  Altimmune, Inc.261
  Aphios Corporation271
  Aradigm Corporation281
  AtralCipan291
  Cellceutix Corporation301
  ContraFect Corporation311
  Dynavax Technologies Corporation321
  Emergent BioSolutions Inc.331
  GlaxoSmithKline Plc341
  Green Cross Corporation351
  Grifols, S.A.361
  Hawaii Biotech, Inc.371
  iBio, Inc.381
  Merck &Co., Inc.391
  Microbiotix, Inc.401
  NanoBio Corporation411
  PaxVax, Inc.421
  Pfenex Inc.431
  PharmAthene, Inc.441
  Planet Biotechnology Inc.451
  Protein Potential, LLC461
  ProThera Biologics, LLC.471
  Soligenix, Inc.481
  Syntiron LLC491
  Tetraphase Pharmaceuticals Inc.501
  United Therapeutics Corporation511
  VLP Biotech, Inc.521
Anthrax Therapeutics Assessment5310
  Assessment by Monotherapy Products531
  Assessment by Combination Products541
  Assessment by Target552
  Assessment by Mechanism of Action572
  Assessment by Route of Administration592
  Assessment by Molecule Type612
Drug Profiles6375
  anthrax (virus like particles) vaccine Drug Profile631
  anthrax + plague vaccine Drug Profile641
  anthrax vaccine Drug Profile652
  anthrax vaccine Drug Profile671
  anthrax vaccine Drug Profile681
  anthrax vaccine Drug Profile691
  anthrax vaccine Drug Profile701
  anthrax vaccine Drug Profile711
  anthrax vaccine Drug Profile721
  anthrax vaccine 2 Drug Profile732
  Antisense RNAi Oligonucleotide to Inhibit ANTXR1 and ANTXR2 for Anthrax Drug Profile751
  ARD-3100 Drug Profile764
  AV-7909 Drug Profile802
  CF-306 Drug Profile821
  CF-307 Drug Profile831
  CF-308 Drug Profile841
  ciprofloxacin hydrochloride Drug Profile851
  DPX-Anthrax Drug Profile862
  DV-230 Drug Profile881
  Epimerox Drug Profile891
  GC-1109 Drug Profile901
  GREANX Drug Profile911
  Human Antibody Based Vaccines Drug Profile922
  KKL-35 Drug Profile941
  Marinus Drug Profile951
  Monoclonal Antibody for Respiratory Anthrax Drug Profile961
  Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax Drug Profile971
  PBI-220 Drug Profile982
  Peptides to Disrupt Cell Membrane for Infectious Diseases Drug Profile1001
  PMX-0196 Drug Profile1011
  PMX-0243 Drug Profile1021
  PMX-225 Drug Profile1031
  PMX-231 Drug Profile1041
  PMX-255 Drug Profile1051
  PreviThrax Drug Profile1062
  Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis Drug Profile1081
  Px-563L Drug Profile1092
  Px-563L Second Generation Drug Profile1111
  raxibacumab Drug Profile1121
  RC-100b Drug Profile1131
  RiVax + SGX-204 Drug Profile1141
  Small Molecule to Inhibit DNA Helicase for Infectious Diseases Drug Profile1151
  Small Molecule to Inhibit Enoyl-Reductase for Anthrax and Tularaemia Drug Profile1161
  Small Molecules for Anthrax Drug Profile1171
  Small Molecules for Bacterial Infections Drug Profile1181
  Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax Drug Profile1191
  Small Molecules to Inhibit Lethal Factor for Anthrax Drug Profile1202
  Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis Drug Profile1221
  Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections Drug Profile1231
  solithromycin Drug Profile12412
  TP-271 Drug Profile1362
Anthrax Dormant Projects1384
Anthrax Discontinued Products1421
Anthrax Product Development Milestones14310
  Featured News &Press Releases1431
    Jun 22, 2016: U.S. Government Issues Solicitation Notices Providing Path to Achieve a Stockpile to Protect 25 Million People Through Procurement of Up to 56.4 Million Doses of NuThrax Vaccines1431
    Sep 10, 2015: Cempra to Present Data From Antibiotic Drug Solithromycin at ICAAC/ICC 2015 Meeting1441
    Aug 17, 2015: Pfenex Awarded HHS Contract Valued At Up To $143.5 Million For The Advanced Development Of Next Generation Anthrax Vaccine1451
    Mar 24, 2015: Emergent BioSolutions Awarded $31 Million Contract for Advanced Development of NuThrax, a Next Generation Anthrax Vaccine1451
    Mar 09, 2015: Pfenex Exercises Glide Contract Extension for Solid Dose Formulation of Recombinant Protective Antigen (rPA)-Based Anthrax Vaccine1461
    Jan 28, 2015: Immunovaccine Study Demonstrates Early Protection Against Anthrax with Single Dose Experimental Vaccines1461
    Dec 29, 2014: Soligenix Announces Publication of Combination Ricin/Anthrax Vaccine Data1471
    Dec 22, 2014: Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L1481
    Oct 21, 2014: Immunovaccine Demonstrates Protection Against Lethal Anthrax Challenge with Rapid Acting, Single Dose Vaccine1481
    Sep 08, 2014: Emergent BioSolutions Awarded Contract to Develop a Dry Formulation of NuThrax, a Next Generation Anthrax Vaccine1491
    Apr 01, 2014: Immunovaccine and Pfenex Report Positive Results From Single Dose Anthrax Vaccine Studies1491
    Dec 17, 2013: Pfenex Awarded Contract For Development Of Next Generation rPA-Based Anthrax Vaccine1501
    Dec 17, 2013: Pfenex Awarded Contract For Development Of Next Generation rPA-Based Anthrax Vaccine1511
    Nov 05, 2013: Pfenex Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine1511
    Sep 19, 2013: GSK signs a multi-year agreement with BARDA to supply the US government with anthrax treatment1512
Appendix1532
  Methodology1531
  Coverage1531
  Secondary Research1531
  Primary Research1531
  Expert Panel Validation1531
  Contact Us1531
  Disclaimer1541

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Anthrax - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Anthrax-Pipeline-Review-H2-2016-2088-16247>
  
APA:
Global Markets Direct - Market Research. (2016). Anthrax - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Anthrax-Pipeline-Review-H2-2016-2088-16247>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.